Marijn E. Dekkers net worth and biography

Marijn Dekkers Biography and Net Worth

Director of Ginkgo Bioworks

Marijn E. Dekkers is founder and chairman of Novalis LifeSciences LLC, an investment and advisory firm for the Life Science industry that he founded in 2017.

From 2010-2016, Dr. Dekkers served as CEO of Bayer AG in Leverkusen, Germany. From 2002-2009, he was CEO of Thermo Fisher Scientific in Waltham, MA, USA. He started his career in 1985 as a research scientist at General Electric’s Corporate R&D Center in Niskayuna, NY, USA.

Dr. Dekkers received his PhD and M.S. in Chemical Engineering from the University of Eindhoven and his B.S in chemistry from the Radboud University, both in the Netherlands. He holds dual U.S. and Dutch citizenship.

What is Marijn E. Dekkers' net worth?: The estimated net worth of Marijn E. Dekkers is at least $55.59 million as of May 16th, 2024. Dr. Dekkers owns 5,515,364 shares of Ginkgo Bioworks stock worth more than $55,594,869 as of December 21st. This net worth approximation does not reflect any other investments that Dr. Dekkers may own. Learn More about Marijn E. Dekkers' net worth.
How do I contact Marijn E. Dekkers?: The corporate mailing address for Dr. Dekkers and other Ginkgo Bioworks executives is 955 Fifth Avenue, New York NY, 10075. Ginkgo Bioworks can also be reached via phone at 877-442-5362 and via email at [email protected]. Learn More on Marijn E. Dekkers' contact information.
Has Marijn E. Dekkers been buying or selling shares of Ginkgo Bioworks?: Marijn E. Dekkers has not been actively trading shares of Ginkgo Bioworks in the last ninety days. Most recently, Marijn E. Dekkers sold 265,000 shares of the business's stock in a transaction on Thursday, May 16th. The shares were sold at an average price of $0.83, for a transaction totalling $219,950.00. Following the completion of the sale, the director now directly owns 5,515,364 shares of the company's stock, valued at $4,577,752.12. Learn More on Marijn E. Dekkers' trading history.
Who are Ginkgo Bioworks' active insiders?: Ginkgo Bioworks' insider roster includes Barry Canton (Major Shareholder), Marijn Dekkers (Director), Mark Dmytruk (Insider), Christian Henry (Director), Jason Kelly (Insider), Reshma Shetty (Insider), and Harry Sloan (Director). Learn More on Ginkgo Bioworks' active insiders.
Are insiders buying or selling shares of Ginkgo Bioworks?: In the last twelve months, Ginkgo Bioworks insiders bought shares 1 times. They purchased a total of 297,619 shares worth more than $270,833.29. In the last twelve months, insiders at the sold shares 10 times. They sold a total of 548,626 shares worth more than $538,373.82. The most recent insider tranaction occured on December, 4th when insider Steven P Coen sold 330 shares worth more than $3,181.20. Insiders at Ginkgo Bioworks own 9.7% of the company. Learn More about insider trades at Ginkgo Bioworks.
Information on this page was last updated on 12/4/2024.

Marijn E. Dekkers Insider Trading History at Ginkgo Bioworks

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
5/16/2024	Sell	265,000	$0.83	$219,950.00	5,515,364
11/3/2022	Sell	171,455	$2.56	$438,924.80	2,021,132

Marijn E. Dekkers Buying and Selling Activity at Ginkgo Bioworks

Ginkgo Bioworks Company Overview

Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops platform for cell programming in the United States. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. It serves pharma and biotech, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.

Today's Range

Now: $10.08

$8.40

$10.53

50 Day Range

MA: $8.56

$6.33

$11.66

2 Week Range

Now: $10.08

$5.26

$74.00

Volume

3,320,731 shs

Average Volume

1,176,131 shs

Market Capitalization

$579.39 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.17

Why Buffett, Griffin and 100 members of Congress are Piling into this One Investment

From Behind the Markets | Ad

This isn't just another investment. It might be the last retirement stock you'll ever need. But this window of opportunity is closing fast.

Click here for the ticker >>>